Legend Biotech Corp (LEGN) Stock Price, Financials & Summary

Price chart

Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19Oct 22

Key dataOct 22, 2026

Open$18.42

From 52W high−47.91%

Volume1.20M

Market cap$3.68B

P/E (TTM)—

P/S (TTM)2.9x

Div yield—

Key dataOct 22, 2026

Open

$18.42

From 52W high

−47.91%

Volume

1.20M

Market cap

$3.68B

ValuationView details →

P/E (Fwd)

32.4x

EV/EBITDA

1454.0x

P/E (TTM)

—

RSI (14)

48.1

MomentumView details →

1D Return

+1.45%

YTD Return

−13.87%

SummaryUpdated Jun 1, 2026

Legend Biotech Corporation (NASDAQ:LEGN) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Somerset, New Jersey. The company is a subsidiary of Genscript Biotech Corporation and went public in June 2020. Legend Biotech specializes in developing innovative cell therapies, particularly CAR-T (Chimeric Antigen Receptor T-cell) therapies for treating various cancers and other diseases. The company has achieved significant commercial success with its lead product CARVYKTI, which has become a leading treatment for multiple myeloma, and continues to expand its pipeline of cell therapy candidates targeting both blood cancers and solid tumors.

Ask drillr about Legend Biotech Corp →

ValuationView details →

P/E (Fwd)

32.4x

P/E (TTM)

—

EV/EBITDA

1454.0x

EV/Sales

2.4x

P/S (TTM)

2.9x

P/B (TTM)

3.0x

ProfitabilityView details →

Gross Margin

56.58%

Net Margin

−7.21%

EBITDA Margin

0.16%

ROE (TTM)

−7.45%

ROA (TTM)

−5.23%

Asset Turnover

0.76x

GrowthView details →

Revenue YoY

+59.54%

EPS YoY

+79.59%

FCF YoY

+11.98%

Revenue CAGR 3Y

+106.41%

EPS CAGR 3Y

−64.95%

EBITDA YoY

+100.79%

MomentumView details →

1D Return

+1.45%

YTD Return

−13.87%

1Y Return

−40.87%

RSI (14)

48.1

vs 50D SMA

−4.22%

vs 200D SMA

−15.66%

Capital & dividendView details →

Debt/Equity

0.23x

Current Ratio

3.04x

Quick Ratio

2.94x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$0.09

EPS Surprise

−25.00%

Beats (12Q)

9/12

Next Q EPS Est

$0.03

Avg Surprise (4Q)

−151.67%

Rev Surprise

8.86%

Financials snapshotView financials →

Revenue (TTM)

1.27B

Net Income (TTM)

−91.60M

Op. CF (TTM)

−183.10M

Next earningsNov 11, 2026 →

Latest newsMore news →

Legend Biotech presented five-year data for CARVYKTI showing that half of patients with relapsed or refractory multiple myeloma remained progression-free and alive five years after a single infusion, with a five-year overall survival rate of 69.2%.28d ago

Similar companies

AbCellera Biologics Inc.ABCL Mirxes Holding Company Limited02629.HK Qyuns Therapeutics Co., Ltd.02509.HK Veracyte, Inc.VCYT Ocumension Therapeutics01477.HK Amylyx Pharmaceuticals, Inc.AMLX Find similar companies →

Latest newsMore news →

Legend Biotech Corp announced that CARVYKTI had net trade sales of approximately $710 million for the quarter ended September 30, 2026, based on information provided by JOHNSON & JOHNSON and not independently verified by Legend Biotech Corp or GenScript.10d ago Legend Biotech presented five-year data for CARVYKTI showing that half of patients with relapsed or refractory multiple myeloma remained progression-free and alive five years after a single infusion, with a five-year overall survival rate of 69.2%.28d ago